5-HT2C receptors inhibit and 5-HT1A receptors activate the generation of spike-wave discharges in a genetic rat model of absence epilepsy

R. Jakus, Marton Graf, G. Juhász, Katalin Gerber, Gyorgy Levay, P. Halász, G. Bagdy

Research output: Article

48 Citations (Scopus)

Abstract

The present study was conducted to investigate the role of 5-HT 2C and 5-HT1A receptors in the generation of spike-wave discharges (SWD) in the genetic absence epilepsy model Wistar Albino Glaxo rats from Rijswijk, Netherlands (WAG/Rij rats). We have determined the effects of the 5-HT2C receptor preferring agonist m-chlorophenyl-piperazine (m-CPP), the selective 5-HT2C receptor antagonist SB-242084, the selective 5-HT1A receptor antagonist WAY-100635, two selective serotonin re-uptake inhibitors (SSRI, fluoxetine and citalopram) and their combinations in this model. The 5-HT2C agonist m-CPP caused marked, dose-dependent decreases in the cumulative duration and number of SWD administered either intraperitoneally (0.9 and 2.5 mg/kg) or intracerebroventricularly (0.05 and 0.1 mg/kg). Treatment with SB-242084 (0.2 mg/kg, ip) alone failed to cause any significant change in SWD compared to vehicle. Pretreatment with SB-242084 (0.2 mg/kg, ip) eliminated the effects of m-CPP on SWD. Fluoxetine (5.0 mg/kg, ip) alone caused moderate increase in SWD. After pretreatment with SB-242084, the effect of fluoxetine was significantly enhanced. The combination of SB-242084 and citalopram (2.5 mg/kg, ip) caused a similar effect, namely an increase in SWD. In contrast, pretreatment with WAY-100635 significantly attenuated the effect of fluoxetine. In conclusion, these results indicate that the increase in endogenous 5-HT produces a dual effect on SWD; the inhibition of epileptiform activity is mediated by 5-HT 2C, the activation by 5-HT1A receptors.

Original languageEnglish
Pages (from-to)964-972
Number of pages9
JournalExperimental Neurology
Volume184
Issue number2
DOIs
Publication statusPublished - dec. 2003

Fingerprint

Receptor, Serotonin, 5-HT2C
Absence Epilepsy
Receptor, Serotonin, 5-HT1A
Genetic Models
Fluoxetine
Serotonin
Citalopram
Serotonin 5-HT2 Receptor Agonists
Serotonin 5-HT1 Receptor Antagonists
Serotonin 5-HT2 Receptor Antagonists
Serotonin Uptake Inhibitors
Netherlands
6-chloro-5-methyl-1-((2-(2-methylpyrid-3-yloxy)pyrid-5-yl)carbamoyl)indoline
piperazine

ASJC Scopus subject areas

  • Neurology
  • Neuroscience(all)

Cite this

@article{d058d29e8d20467898e630206b08963d,
title = "5-HT2C receptors inhibit and 5-HT1A receptors activate the generation of spike-wave discharges in a genetic rat model of absence epilepsy",
abstract = "The present study was conducted to investigate the role of 5-HT 2C and 5-HT1A receptors in the generation of spike-wave discharges (SWD) in the genetic absence epilepsy model Wistar Albino Glaxo rats from Rijswijk, Netherlands (WAG/Rij rats). We have determined the effects of the 5-HT2C receptor preferring agonist m-chlorophenyl-piperazine (m-CPP), the selective 5-HT2C receptor antagonist SB-242084, the selective 5-HT1A receptor antagonist WAY-100635, two selective serotonin re-uptake inhibitors (SSRI, fluoxetine and citalopram) and their combinations in this model. The 5-HT2C agonist m-CPP caused marked, dose-dependent decreases in the cumulative duration and number of SWD administered either intraperitoneally (0.9 and 2.5 mg/kg) or intracerebroventricularly (0.05 and 0.1 mg/kg). Treatment with SB-242084 (0.2 mg/kg, ip) alone failed to cause any significant change in SWD compared to vehicle. Pretreatment with SB-242084 (0.2 mg/kg, ip) eliminated the effects of m-CPP on SWD. Fluoxetine (5.0 mg/kg, ip) alone caused moderate increase in SWD. After pretreatment with SB-242084, the effect of fluoxetine was significantly enhanced. The combination of SB-242084 and citalopram (2.5 mg/kg, ip) caused a similar effect, namely an increase in SWD. In contrast, pretreatment with WAY-100635 significantly attenuated the effect of fluoxetine. In conclusion, these results indicate that the increase in endogenous 5-HT produces a dual effect on SWD; the inhibition of epileptiform activity is mediated by 5-HT 2C, the activation by 5-HT1A receptors.",
keywords = "5-HT receptor, 5-HT receptor, Epilepsy, SB-242084, Serotonin, Spike-wave discharge, SSRI antidepressant, WAY-100635",
author = "R. Jakus and Marton Graf and G. Juh{\'a}sz and Katalin Gerber and Gyorgy Levay and P. Hal{\'a}sz and G. Bagdy",
year = "2003",
month = "12",
doi = "10.1016/S0014-4886(03)00352-2",
language = "English",
volume = "184",
pages = "964--972",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - 5-HT2C receptors inhibit and 5-HT1A receptors activate the generation of spike-wave discharges in a genetic rat model of absence epilepsy

AU - Jakus, R.

AU - Graf, Marton

AU - Juhász, G.

AU - Gerber, Katalin

AU - Levay, Gyorgy

AU - Halász, P.

AU - Bagdy, G.

PY - 2003/12

Y1 - 2003/12

N2 - The present study was conducted to investigate the role of 5-HT 2C and 5-HT1A receptors in the generation of spike-wave discharges (SWD) in the genetic absence epilepsy model Wistar Albino Glaxo rats from Rijswijk, Netherlands (WAG/Rij rats). We have determined the effects of the 5-HT2C receptor preferring agonist m-chlorophenyl-piperazine (m-CPP), the selective 5-HT2C receptor antagonist SB-242084, the selective 5-HT1A receptor antagonist WAY-100635, two selective serotonin re-uptake inhibitors (SSRI, fluoxetine and citalopram) and their combinations in this model. The 5-HT2C agonist m-CPP caused marked, dose-dependent decreases in the cumulative duration and number of SWD administered either intraperitoneally (0.9 and 2.5 mg/kg) or intracerebroventricularly (0.05 and 0.1 mg/kg). Treatment with SB-242084 (0.2 mg/kg, ip) alone failed to cause any significant change in SWD compared to vehicle. Pretreatment with SB-242084 (0.2 mg/kg, ip) eliminated the effects of m-CPP on SWD. Fluoxetine (5.0 mg/kg, ip) alone caused moderate increase in SWD. After pretreatment with SB-242084, the effect of fluoxetine was significantly enhanced. The combination of SB-242084 and citalopram (2.5 mg/kg, ip) caused a similar effect, namely an increase in SWD. In contrast, pretreatment with WAY-100635 significantly attenuated the effect of fluoxetine. In conclusion, these results indicate that the increase in endogenous 5-HT produces a dual effect on SWD; the inhibition of epileptiform activity is mediated by 5-HT 2C, the activation by 5-HT1A receptors.

AB - The present study was conducted to investigate the role of 5-HT 2C and 5-HT1A receptors in the generation of spike-wave discharges (SWD) in the genetic absence epilepsy model Wistar Albino Glaxo rats from Rijswijk, Netherlands (WAG/Rij rats). We have determined the effects of the 5-HT2C receptor preferring agonist m-chlorophenyl-piperazine (m-CPP), the selective 5-HT2C receptor antagonist SB-242084, the selective 5-HT1A receptor antagonist WAY-100635, two selective serotonin re-uptake inhibitors (SSRI, fluoxetine and citalopram) and their combinations in this model. The 5-HT2C agonist m-CPP caused marked, dose-dependent decreases in the cumulative duration and number of SWD administered either intraperitoneally (0.9 and 2.5 mg/kg) or intracerebroventricularly (0.05 and 0.1 mg/kg). Treatment with SB-242084 (0.2 mg/kg, ip) alone failed to cause any significant change in SWD compared to vehicle. Pretreatment with SB-242084 (0.2 mg/kg, ip) eliminated the effects of m-CPP on SWD. Fluoxetine (5.0 mg/kg, ip) alone caused moderate increase in SWD. After pretreatment with SB-242084, the effect of fluoxetine was significantly enhanced. The combination of SB-242084 and citalopram (2.5 mg/kg, ip) caused a similar effect, namely an increase in SWD. In contrast, pretreatment with WAY-100635 significantly attenuated the effect of fluoxetine. In conclusion, these results indicate that the increase in endogenous 5-HT produces a dual effect on SWD; the inhibition of epileptiform activity is mediated by 5-HT 2C, the activation by 5-HT1A receptors.

KW - 5-HT receptor

KW - 5-HT receptor

KW - Epilepsy

KW - SB-242084

KW - Serotonin

KW - Spike-wave discharge

KW - SSRI antidepressant

KW - WAY-100635

UR - http://www.scopus.com/inward/record.url?scp=0842299485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0842299485&partnerID=8YFLogxK

U2 - 10.1016/S0014-4886(03)00352-2

DO - 10.1016/S0014-4886(03)00352-2

M3 - Article

C2 - 14769389

AN - SCOPUS:0842299485

VL - 184

SP - 964

EP - 972

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - 2

ER -